Results 161 to 170 of about 240,836 (199)
Some of the next articles are maybe not open access.
Blood Coagulation and Fibrinolysis
Objective Andexanet alfa is a targeted reversal agent for life threatening hemorrhage associated with direct acting oral anticoagulants (DOACs), but there is uncertainty regarding the benefit when compared to 4-factor prothrombin complex concentrate (4F ...
Vivian M Irizarry-Gatell +7 more
semanticscholar +1 more source
Objective Andexanet alfa is a targeted reversal agent for life threatening hemorrhage associated with direct acting oral anticoagulants (DOACs), but there is uncertainty regarding the benefit when compared to 4-factor prothrombin complex concentrate (4F ...
Vivian M Irizarry-Gatell +7 more
semanticscholar +1 more source
Emergency Medicine Journal
Background Andexanet alfa was approved in 2018 for reversal of direct oral anticoagulants but due to issues of cost and access, four-factor prothrombin complex concentrate (4F-PCC) continues to be used for this indication.
Erin Sadek +3 more
semanticscholar +1 more source
Background Andexanet alfa was approved in 2018 for reversal of direct oral anticoagulants but due to issues of cost and access, four-factor prothrombin complex concentrate (4F-PCC) continues to be used for this indication.
Erin Sadek +3 more
semanticscholar +1 more source
Safety of Andexanet Alfa Use in Cardiac Surgery
Journal of Cardiothoracic and Vascular Anesthesia, 2023Jiapeng Huang +7 more
openaire +2 more sources